Relmada Therapeutics Inc
NASDAQ:RLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biohit Oyj
OMXH:BIOBV
|
FI |
Relmada Therapeutics Inc
Total Current Assets
Relmada Therapeutics Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
Total Current Assets
$94m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
20%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Assets
$55.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Assets
$29.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Assets
$42.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Assets
$43.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Assets
$55.6B
|
CAGR 3-Years
46%
|
CAGR 5-Years
26%
|
CAGR 10-Years
16%
|
|
Relmada Therapeutics Inc
Glance View
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Coral Gables, Florida and currently employs 10 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).
See Also
What is Relmada Therapeutics Inc's Total Current Assets?
Total Current Assets
94m
USD
Based on the financial report for Dec 31, 2025, Relmada Therapeutics Inc's Total Current Assets amounts to 94m USD.
What is Relmada Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
20%
Over the last year, the Total Current Assets growth was 105%. The average annual Total Current Assets growth rates for Relmada Therapeutics Inc have been -15% over the past three years , -4% over the past five years , and 20% over the past ten years .
